IDM, CAMBRIDGE LABORATORIES SIGN AGREEMENT

IDM (Immuno-Designed Molecules), a privately held biopharmaceutical company, the shareholders of which recently entered into an agreement to combine with Epimmune, today announced that it has signed an exclusive marketing agreement for Junovan (Mepact or L-MTP-PE) in the United Kingdom and Ireland with Cambridge Laboratories, a privately owned British pharmaceutical company. Junovan, known as Mepact throughout clinical development, is the brand name the product will be marketed under worldwide, upon obtaining necessary regulatory approvals.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20406020&full=1)